We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
The Best of the Best |

Top-Accessed Article: Successful Treatment of Vitiligo With 0.1% Tacrolimus Ointment FREE

Rebat M. Halder, MD; Ife J. Rodney, MD
[+] Author Affiliations

Author Affiliations: Department of Dermatology, Howard University College of Medicine, Washington, DC.

Arch Dermatol. 2012;148(12):1432. doi:10.1001/archdermatol.2012.2385.
Text Size: A A A
Published online

Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol. 2003;139(5):571-574.

In this article, Travis and colleagues report 3 cases of vitiligo that were successfully treated with tacrolimus ointment. Although the number of cases is small, this report is notable because it describes patients with disease that was refractory to treatment with both topical corticosteroids and phototherapy, mainstays of therapy for vitiligo. Tacrolimus ointment was well tolerated in these patients, with no local adverse effects. It is an excellent alternative to topical corticosteroid therapy for vitiligo, especially in the face and intertriginous areas, where the risk of steroid atrophy is of major concern, and can also be used in areas that are not easily accessible to phototherapy. It is well tolerated in both children and adults.

Since the publication of this article, topical calcineurin inhibitors (tacrolimus ointment and pimecrolimus cream) are now commonly used in the treatment of vitiligo. In 2005, the Food and Drug Administration issued “black box” warnings for tacrolimus ointment and pimecrolimus cream because of potential safety risks, including lymphomas and skin cancers. Although, to our knowledge, there is currently no scientific evidence of increased risk of malignancy, care should still be taken when these medications are being prescribed for prolonged periods or for use on large body surface areas of vitiligo.

From October 2010 to August 2011, this article was accessed 2014 times on the Archives of Dermatology website.


Contact Dr Halder at the Department of Dermatology, Howard University College of Medicine, 2041 Georgia Ave NW, Washington, DC 20060 (rhalder@howard.edu).

Conflict of Interest Disclosures: Dr Halder has served as a consultant to Combe Corp, L’Oreal USA, and Momelan Technologies and has received royalties from Informa.





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Related Content

Customize your page view by dragging & repositioning the boxes below.